Citeline and Norstella Unite to Offer Life Sciences Clients a Full Suite of Commercial and Clinical Solutions
The new organization will help life sciences companies improve strategic decision-making and accelerate the mission of smoothing access to therapy from pipeline to patient
Yardley, PA, June 28, 2022 (GLOBE NEWSWIRE) -- Norstella, an organization that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)—a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance—have announced an agreement to merge the companies.
By uniting Norstella, which is comprised of four prominent pharmaceutical solutions providers—Evaluate, MMIT, Panalgo and The Dedham Group—with Citeline, the combined company will be well positioned to help life sciences companies reach patients faster by providing clients with the intelligence and answers they need from early clinical development through to commercialization. This move reflects the shared goal of becoming an end-to-end solution provider, helping patients access life-saving therapies.
As life sciences companies drive innovation toward more specialized therapeutics across all disease areas including oncology and rare disease, and patient populations become more targeted, they need to make critical decisions about how to bring the right drugs to market, how to construct clinical trials leveraging the latest innovations in real-world data and data science—and with end points that consider future payer reimbursement decisions—and, ultimately, how to reach patients in need.
“Accelerating innovation and ensuring that every patient gets the therapy that they need is our North Star,” said Norstella CEO Mike Gallup. “By bringing clinical and commercial intelligence together—along with real-world data—the combined company will be well positioned to deliver on its mission.”
Together, Norstella and Citeline will play a critical role in helping pharmaceutical manufacturers plan for and overcome barriers to access, not just during clinical trials but at every stage in the drug development life cycle. Citeline’s solutions, including its portfolio of clinical trial products, provide insights that improve the speed and efficiency of clinical trials and reduce risk. Now, the Citeline solutions—along with MMIT’s PAR data and other complementary Norstella data assets—can be powered by Panalgo’s Instant Health Data Analytics platform to provide transformative answers that will improve workflow and decision-making and, ultimately, help products get to market and to patients quicker than ever before.
“At Citeline, our mission is to accelerate the connection of treatments to patients and patients to treatments. Ultimately, this marriage of commercial and clinical capabilities will advance the mission and enable the pharmaceutical C-suite to manage portfolio strategy like never before,” said Ramsey Hashem, CEO, and Jay Nadler, Executive Chair, of Citeline. “This includes deciding which drug to bring to market, what new indications to pursue for a drug and how to target patients for clinical trials more quickly and with reduced cost. And now, this includes understanding how to design clinical trials that yield the types of data that payers need to make appropriate reimbursement and formulary decisions.”
“It’s about making a difference in the lives of patients,” said Gallup. “This move will help us make our vision of a more innovative, accessible healthcare marketplace a reality.”
The merger is expected to close in the second half of 2022 subject to customary closing conditions and regulatory approvals.
At Norstella, our mission is simple: to help patients gain access to life-saving therapies. Norstella consists of several prominent organizations—Evaluate, MMIT, Panalgo and The Dedham Group—that have united to offer a full range of pharmaceutical consultancy services and solutions. As one organization, Norstella provides life sciences clients with the right tools and expertise to navigate complexities at each step of the drug development life cycle, from pipeline to patient. For more information, visit Norstella and follow on LinkedIn.
Citeline (formerly Pharma Intelligence) powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory related-decisions and create real-world opportunities for growth.
Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
IBFD announces a new online transfer pricing qualification to further enhance its tax training offering10.8.2022 10:00:00 CEST | Press release
AMSTERDAM, Aug. 10, 2022 (GLOBE NEWSWIRE) -- IBFD has released the new Advanced Professional Certificate in Transfer Pricing – II (APTCP-II). This market-leading online qualification is aimed at professionals who have a basic understanding about the principles of transfer pricing and wish to enhance their knowledge further in this field. How is the course structured? Starting on 1 November 2022, the six-month programme consists of four courses, each containing several modules that guide you on transfer pricing at an intermediate level in the following areas: Transfer Pricing and Business RestructuringTransfer Pricing ControversyTransfer Pricing and Indirect TaxationOperational Transfer Pricing What skills will you gain? The key skills that you will learn and be able to put into practice are: Be able to determine the transfer pricing aspects of business restructuringsBuild and apply a transfer pricing controversy framework, detect risks and understand various dispute mechanismsDefine a
Release of Marimekko's Half-year Financial report, 1 January–30 June 202210.8.2022 10:00:00 CEST | Press release
Marimekko Corporation, Press release 10 August 2022 at 11.00 a.m. Release of Marimekko's Half-year Financial report, 1 January–30 June 2022 Marimekko Corporation’s Half-year Financial Report 1 January–30 June 2022 will be published on Wednesday 17 August 2022 at 8.00 a.m. EEST. The report and related materials will be available on the company’s website at https://company.marimekko.com/en/investors/ after the publication. A media and investor conference will be held in English on 17 August 2022 at 2.00 p.m. EEST. A live webcast of the conference can be followed at https://marimekko.videosync.fi/q2-2022-results, and a recording of the webcast will be available at the same address later. Questions can be asked during the live webcast in writing. Additional information: Anna Tuominen, Marimekko Communications Tel. +358 40 584 6944 firstname.lastname@example.org DISTRIBUTION: Key media Marimekko is a Finnish lifestyle design company renowned for its original prints and colors. The company’s pr
Aspo Group half-year financial report, January 1 to June 30, 2022: Strong performance continued in Q2; Comparable operating profit reached a record-high EUR 16.0 million10.8.2022 08:30:00 CEST | Press release
Aspo Plc Half-year financial report August 10, 2022, at 9:30 am Aspo Group half-year financial report, January 1 to June 30, 2022 Strong performance continued in Q2: Comparable operating profit reached a record-high EUR 16.0 million Figures from the corresponding period in 2021 are presented in brackets. April–June 2022, continuing operations Aspo’s net sales increased by 16% to EUR 161.4 (139.3) million.Comparable operating profit, at Group total level was EUR 16.0 (9.6) million, and the comparable operating profit rate was 9.7% (6.7%).The comparable operating profit of ESL Shipping was EUR 9.2 (5.4) million, Telko EUR 7.2 (5.5) million, and Leipurin EUR 0.9 (0.3) million.Items affecting the comparability of operating profit totaled EUR -2.4 million at Group total level.Operating profit was EUR 14.8 (9.6) million. The operating profit rate was 9.2% (6.9%).The operating profit of ESL Shipping was EUR 9.0 (5.4) million, Telko EUR 6.8 (5.5) million, and Leipurin EUR 0.4 (0.3) million.Ear
UPDATE ON MBCC ACQUISITION – CLOSING TARGETED FOR H1 202310.8.2022 08:00:00 CEST | Press release
UPDATE ON MBCC ACQUISITION – CLOSING TARGETED FOR H1 2023 The UK Competition and Markets Authority (CMA) has decided to conduct an in-depth examination in the UK market related to Sika’s planned acquisition of MBCC Group. Closing is now targeted for the first half of 2023. The adapted timeline will not impact the strategic attractiveness of the transaction. Guidance for the expected annual synergies remains at CHF 160 – 180 million. In November 2021, Sika signed a definitive agreement to acquire MBCC Group (former BASF Construction Chemicals). The completion of the transaction is subject to regulatory approvals. The UK Competition and Markets Authority (CMA) has decided to conduct an in-depth examination (Phase 2) regarding Sika’s planned acquisition of MBCC Group. This examination will require additional time. The closing of the transaction is therefore now targeted for the first half of 2023 instead of at the end of 2022 as previously announced. Thomas Hasler, Chief Executive Officer
Ahold Delhaize delivers resilient performance in Q2 2022; raises full-year EPS and free cash flow guidance10.8.2022 07:45:00 CEST | Press release
With high levels of inflation, our brands are focused on helping customers efficiently manage their spending. Driven by our €850 million Save For Our Customers cost savings program, our brands are absorbing cost increases for customers, introducing more entry-priced products, expanding high-quality own-brand assortments and delivering personalized value through loyalty programs.Q2 Group net sales increased 6.4% at constant exchange rates to €21.4 billion. At actual exchange rates, net sales grew 15.0%. Q2 net sales accelerated in both regions compared to Q1, growing 7.7% in the U.S. and 4.2% in Europe at constant rates. Increased market share in the majority of markets reflects strong customer loyalty to our locally tailored customer value propositions.Net consumer online sales increased 4.8% at constant exchange rates. Net consumer online sales in grocery increased 11.5% at constant exchange rates, as we continue to invest in creating the leading local omnichannel food experience.Q2 u